Allosteric modulators of A 1 and A 2A adenosine receptors have been described; however, for the A 3 adenosine receptor, neither an allosteric site nor a compound with allosteric effects has been described. In this study, the allosteric modulation of human A 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives was investigated by examining their effects on the dissociation of the agonist radioligand, [
I]I-AB-MECA in a concentration-dependent manner, suggesting an allosteric interaction. These compounds had no effect on the dissociation of the radiolabeled antagonist [ 3 H]PSB-11 from the A 3 adenosine receptor, suggesting a selective enhancement of agonist binding. By comparison, compounds of similar structure (VUF8501, VUF8503, VUF8505), the classical adenosine receptor antagonist CGS15943 and the A 1 receptor allosteric enhancer PD81723 did not significantly influence the dissociation rate of [ 125 I]I-AB-MECA. The effect of agonist on forskolin-induced cAMP production was significantly enhanced by VUF5455. When the subtype-selectivity of the allosteric enhancement was tested the compounds had no effect on the dissociation of either [ Probing of structure-activity relationships suggested that a carbonyl group is essential for allosterism but preferred only for competitive antagonism. The presence of a 7-methyl group decreased the competitive binding affinity without a major loss of the allosteric enhancing activity, suggesting that the structural requirements for allosteric enhancement might be distinct from those for competitive antagonism.
The purine nucleoside adenosine produces numerous physiological actions via cell surface adenosine receptors. These receptors are widely distributed throughout the body and are subclassified as A 1 , A 2A , A 2B , and A 3 adenosine receptors (Fredholm et al., 2000) . All of the receptors belong to the G protein-coupled receptor (GPCR) family.
The A 3 adenosine receptor is the adenosine receptor subtype identified most recently (Zhou et al., 1992) and is involved in a variety of physiological processes (Kaiser and Quinn, 1999) . Stimulation of the A 3 adenosine receptor increases the release of inflammatory mediators, such as histamine, from mast cells (Hannon et al., 1995) . Tumor necrosis factor-␣ production is inhibited at the level of transcription by the activation of the A 3 receptor, which suppresses steady-state mRNA levels (Sajjadi et al., 1996) . The A 3 adenosine receptor is believed to be involved in ischemic preconditioning of the heart and kidney (Strickler et al., 1996; Lee and Emala, 2000) . The activation of the A 3 adenosine receptor is also suggested to be involved in immunosuppression (MacKenzie et al., 1994 ) and brain ischemia (Von Lubitz et al., 1994) . Thus, adenosine receptor agonists and agents that enhance the response to adenosine would have many clinic applications. The clinical application of adenosine analogs as directly acting, potent adenosine receptor agonists has not yet proven successful because of potential side effects. Side effects are caused by the ubiquitous presence of adenosine receptors throughout the body, which are activated by agonists indiscriminately. Thus, it is useful to consider an alternative approach that may activate adenosine receptors in a more specific manner.
Several members of the GPCR superfamily have been reported to be modulated allosterically (Birdsall et al., 1995) . Allosteric modulation of GPCRs has been characterized most extensively for muscarinic receptors , and it has been suggested that allosteric modulators may provide therapeutic advantages over orthosteric agonists. Such advantages may include greater subtype selectivity and fewer side effects (Birdsall et al., 1995; Bhattacharya and Linden, 1996; Linden, 1997) . For example, diazepam and other benzodiazepines, which act as allosteric enhancers of the ion channel-coupled GABA A receptor, have acceptable side effects and are used clinically. In contrast, directly acting GABA A agonists have widespread side effects and are not used clinically. The effects of an allosteric enhancer on an organ or tissue might be event-specific because of an increase in the local concentration of the endogenous agonist. For example, hypoxic conditions increase the local production of cytoprotective adenosine. Compounds that either augment the concentration of adenosine or enhance its action locally may have a better therapeutic profile than the agonists. Additionally, neurotransmitter receptors have been reported to be less sensitive to desensitization or downregulation by allosteric enhancers than by exogenous agonists (Birdsall et al., 1995) . Thus, allosteric modulators could offer a control of receptor function not found with competitive agonists.
Within a family of receptors that bind the same endogenous ligand, the primary binding sites may be similar, because the amino acids that form this site are highly conserved (Tucek and Proska, 1995) . An allosteric site, being spatially distinct from the primary site, may be located at less conserved regions on the receptor, which may provide greater subtype selectivity (Tucek and Proska, 1995; Birdsall et al., 2001) .
Allosteric modulation of A 1 adenosine receptors was reported (Bruns and Fergus, 1990; Linden, 1997) . A number of aminobenzoylthiophenes, including PD81723, were allosteric modulators of the A 1 adenosine receptor (Bruns and Fergus, 1990) . These compounds were shown to be highly subtypeselective enhancers for A 1 adenosine receptors (Bruns and Fergus, 1990) and were less likely to cause desensitization and down-regulation of receptors than selective A 1 adenosine receptor agonists (Bhattacharya and Linden, 1996) . Recently, an allosteric site on the A 2A adenosine receptor was defined . However, it was not known whether there is an allosteric binding site on the A 3 adenosine receptor; compounds with allosteric effects at A 3 adenosine receptors have not been reported previously. This study demonstrated allosteric modulation of A 3 adenosine receptors by a number of 3-(2-pyridinyl)isoquinoline derivatives (Fig. 1, A and B) . Membrane Preparation. Forebrain and striatal tissue from Wistar rats were homogenized in ice-cold 50 mM Tris-HCl buffer, pH 7.7, using an electric homogenizer. The homogenate was centrifuged at 50,000g for 10 min at 4°C, and the pellet was washed in fresh buffer. A pretreatment with adenosine deaminase (2 units/ml) was performed. The final pellet was stored at Ϫ80°until the binding experiments. HEK293 cells expressing human A 3 adenosine receptors and native RBL-2H3 mast cells with native rat A 3 adenosine receptors were harvested by trypsinization. Cells were centrifuged at 500g for 10 min, and the pellet was suspended in 50 mM Tris-HCl buffer, pH 8.0, containing 10 mM MgCl 2 , 1 mM EDTA and 0.1 mg/ml CHAPS. The suspension was homogenized with an electric homogenizer for 5 s, and was then recentrifuged at 18,000g for 30 min at 4°C. The resultant pellets were resuspended in buffer in the presence of 2 U/ml adenosine deaminase, and the suspension was stored at Ϫ80°C. Protein concentrations were measured with the BCA method (Smith et al., 1985) .
Experimental Procedures
Competitive Binding Assays. Binding of 0.15 nM [ 125 I]I-AB-MECA (Olah et al., 1994) to membranes of HEK293 cells expressing human A 3 adenosine receptors (25 g of protein) was carried out in duplicate at 37°C for 1 h in 100 l of 50 mM Tris-HCl buffer, pH 8.0, containing 10 mM MgCl 2 , 1 mM EDTA, and 0.1 mg/ml CHAPS. Nonspecific binding was defined as binding in the presence of 30 M NECA. Tested compounds were dissolved in dimethyl sulfoxide. Control incubations also contained the same concentrations of dimethyl Measurement of cAMP Level. cAMP production was measured by using a commercially available, low-pH cAMP Immunoassay Kit (R&D Systems, Inc.). Briefly, HEK293 cells expressing recombinant human A 3 adenosine receptors were grown to 70% confluence in 12 well plates and then treated with test compounds. Thirty minutes after the treatment, 10 M forskolin was added to the culture medium to stimulate cAMP levels, and was incubated for an additional 15 min at 37°C. Reaction was terminated by the addition of 1 ml of 0.1 N HCl, and the cellular debris was removed by centrifugation for 5 min at 10,000g. All experiments were performed in the presence of 10 M rolipram and 3 U/ml adenosine deaminase. cAMP levels were measured using a Bio-kinetics reader (Bio-Tek instruments Inc., Winooski, VT).
Data Analysis. Binding experiment parameters were estimated using Prism software (GraphPAD, San Diego, CA). IC 50 values obtained from competition curves were converted to K i values by using the Cheng-Prusoff equation. (Fig. 2) was characterized in the absence or presence of the test compounds. The dissociation rate (k Ϫ1 ) in the absence of the test compounds was 0.042 Ϯ 0.005 min Ϫ1 , and the t 1/2 of dissociation was 16.4 Ϯ 2.5 min. The k Ϫ1 values and the half-life in the presence of 3 M (k Ϫ1 ϭ 0.031 Ϯ 0.003 min Ϫ1 ; t 1/2 ϭ 23.2 Ϯ 3.4 min) and 10 M (k Ϫ1 ϭ 0.024 Ϯ 0.003 min Ϫ1 ; half-life ϭ 28.5 Ϯ 4.3 min) VUF5455 (Fig. 1A) were significantly different from those of the control values (p Ͻ 0.05). Compounds VUF8502, VUF8504 and VUF8507 also significantly decreased the dissociation at 10 M (Table 1 ). The potencies of these compounds, as determined by their ability to influence the dissociation rate, were very similar. By contrast, the isoquinoline derivatives VUF8501, VUF8503, and VUF8505 (Fig. 1B) , the A 1 allosteric enhancer PD81723 (Fig. 1C) (Fig. 3) , suggesting that slowing of the dissociation was specific for the agonist state of the A 3 adenosine receptor. 125 I]I-AB-MECA. However, at concentrations Ͼ 1 M, the dissociation rate decreased significantly. Because of the limited solubility of these compounds, the highest concentration used was 30 M. It seemed that higher concentrations of these compounds produced more pronounced effects. (Fig. 6 ). The enhancers also had no effect on the time course for the dissociation of [ 3 H]CGS21680 from A 2A adenosine receptors (Fig. 7) . These results suggest that the 3-(2-pyridinyl)isoquinoline derivatives are selective allosteric modulators for A 3 adenosine receptors.
Results

Effects of the Test Compounds on the
Concentration-Response
Structure-Activity Relationships for the Enhancement of A 3 Adenosine Receptor Binding by 3-(2-Pyridinyl)isoquinoline Derivatives. All of the test compounds that displayed allosteric effects contained a carbonyl group. The replacement of the carbonyl group with an imino group resulted in a loss of the allosteric property of these compounds. The allosteric potencies of the 3-(2-pyridinyl)iso- 
The compound VUF8504 was about 2 orders of magnitude more potent than VUF5455 with respect to competitive binding.
Both the allosteric and competitive potencies of these compounds for rat A 3 adenosine receptors were tested. As shown in Fig. 8 , the effect of VUF5455 and VUF8504 on the dissociation of [
125 I]I-AB-MECA from rat A 3 adenosine receptors was only slightly decreased or similar to that of human A 3 adenosine receptors. In contrast, their competitive binding affinities were approximately 8-and 240-fold less than at human A 3 receptors, for VUF5455 (K i ϭ 12.8 Ϯ 3.1 M) and VUF8504 (K i ϭ 4.2 Ϯ 0.8 M), respectively. This demonstrated that binding enhancement could be separated from competitive antagonism.
Enhancement of the A 3 Adenosine Receptor Function by VUF5455. Direct information regarding the allosteric modulation of A 3 adenosine receptors was obtained from dissociation kinetic experiments. It was important to correlate data from in vitro assays with those estimated from functional experiments. Hence, we conducted a cAMP assay to observe the effects of the allosteric modulator on human A 3 adenosine receptor function. The compound VUF5455 was selected for the cAMP assay, because its competitive binding to A 3 adenosine receptors was relatively weak compared with other analogs. VUF5455 significantly enhanced the effect of Cl-IB-MECA on forskolin-induced cAMP formation. The EC 50 value of Cl-IB-MECA induced inhibition of forskolinstimulated cAMP accumulation was 11.7 Ϯ 2.3 nM. In the presence of 1 and 3 M VUF5455, the EC 50 values were 7.4 Ϯ 1.2 and 6.3 Ϯ 0.8 nM, respectively, which were significantly different from that in the absence of VUF5455 (p Ͻ 0.05). It should be noted that VUF5455 might exert both allosteric enhancement and antagonistic effects in a functional assay. To avoid the confusing influence by the competitive inhibition, the effect of VUF5455 on the concentration-response curve for Cl-IB-MECA was investigated in the presence of the competitive antagonist MRS1220. Under this experimental condition, 10 M VUF5455 caused a 3.2-fold shift to the left in the concentration-response relationship for Cl-IB-MECA (Fig. 9) . The EC 50 values obtained were 232 Ϯ 67.4 and 72.5 Ϯ 18.4 nM (n ϭ 3) in the absence and presence of 10 M VUF5455, respectively, which were significantly different (p Ͻ 0.05). 3 H]R-PIA to A 1 adenosine receptors in rat forebrain membranes was carried out at 37°C for 90 min 50 mM Tris-HCl buffer, pH 7.7, in a total assay volume of 400 l. The dissociation was begun by addition of 10 M CPA in the absence or presence of the tested compound. Nonspecific binding was determined using 10 M CPA. Samples were filtered after incubation at 37°C at the time points indicated. The data shown were derived from one experiment performed in duplicate and are typical of three independent experiments giving similar results. 
Discussion
This study provided evidence that several 3-(2-pyridinyl)isoquinoline derivatives were allosteric enhancers of the A 3 adenosine receptor. The allosteric interaction was shown by the slowing of the dissociation of the agonist radioligand [ 125 I]I-AB-MECA from A 3 adenosine receptors.
The 3-(2-pyridinyl)isoquinoline derivatives were discovered as potential antagonists for A 3 adenosine receptors (van Muijlwijk-Koezen et al., 1998) . Previous studies demonstrated that the 3-(2-pyridinyl)isoquinoline derivative VUF8505 was a moderately potent and selective competitive antagonist for A 3 adenosine receptors (van Muijlwijk-Koezen et al., 1998) . The present study further demonstrated that this compound acts on human A 3 adenosine receptors via the competitive binding site, but not an allosteric site.
VUF8504 was approximately 2 orders of magnitude more potent than VUF5455 in displacing [
125 I]I-AB-MECA binding, whereas the allosteric potencies of the two compounds were similar. A benzamide carbonyl group on the isoquinoline derivatives (Fig. 1A) was required for allosteric enhancement of A 3 agonist binding, whereas the corresponding imines (Fig. 1B) did not enhance A 3 agonist binding. These results showed that there were distinct structural requirements for allosteric enhancement of A 3 adenosine receptor binding, and these requirements were different from those for competitive A 3 antagonistic activity. For these two derivatives, species differences in A 3 antagonist potency were pronounced, whereas the allosteric effects were comparable in rat and human. Apparently, it was possible to achieve some separation between allosteric and antagonistic activity of these compounds.
The compounds described in this study may serve as the first generation of allosteric enhancers for A 3 adenosine receptors. Allosteric enhancers of A 3 adenosine receptors may be of potential clinical use; however, application of the modulators as described in this study may have several limitations. An obvious factor that may limit the use of these agents is their antagonistic activities, which will tend to suppress any enhancing actions of these compounds. However, it seems that the structure-activity relationships for allosteric enhancement are separable from those for competitive antagonism, suggesting that it may be possible to discover compounds with improved enhancing activity that lack antagonist activity. Other limitations of these compounds include their low aqueous solubility (around 50 M) and their modest allosteric potencies. Furthermore, the specificity of these compounds for adenosine receptors compared with other receptors has not been investigated. Hence, the possibility of other interfering activities cannot be excluded.
The identification of allosteric sites on receptors offers new pharmacological approaches to modulate receptor function. Although it is not known whether an allosteric site is a general feature of the GPCR family, increasing numbers of GPCRs are reported to be modulated allosterically by certain compounds. These include: metabotropic glutamate (Litschig et al., 1999) , Ca 2ϩ (Conigrave et al., 2000) , P2Y (Nepveu et al., 1998; Conigrave et al., 2000) , muscarinic , adenosine (Kourounakis et al., 2000) , adrenergic (Leppik et al., 2000) , dopamine (Hoare et al., 2000) , 5-hydroxytryptamine (Thomas et al., 1997) , tachykinin (Knaus et al., 1991; Croci et al., 1998) , angiotensin AT 1 (Purdy et al., 1993) , and oxytocin receptors (Grazzini et al., 1998) . Although no GPCR allosteric enhancer is presently in clinical use, much progress has been made toward the allosteric modulation of this receptor family. Muscarinic receptor researchers currently use the radiolabeled allosteric ligand W84 as a probe to characterize the allosteric site on that receptor (Trä nkle et al., 1998) . Allosteric enhancers were found with almost absolute selectivity for certain subtypes of muscarinic receptors (Birdsall et al., 2001 ). This subtype selectivity was considered very difficult to achieve otherwise by targeting the recognition site on the receptor (Tucek and Proska, 1995) . The allosteric enhancers of adenosine receptors have a potential advantage as therapeutic agents over adenosine receptor agonists [i.e., they seem less likely to cause desensitization and down-regulation of the receptor (Bhattacharya and Linden, 1996) ]. The concept that an allosteric recognition site might serve as an alternate means to effect receptor activation was proposed and demonstrated for several G protein-coupled receptors, including muscarinic (Jakubik et al., 1996) , 5-hydroxytryptamine 7 (Thomas et al., 1997) , P2Y (Conigrave et al., 2000) , and Ca 2ϩ receptors (Conigrave et al., 2000; Kobilka, 2000) .
In the absence of mutation data for the allosteric effect, it is not yet possible to locate the allosteric site or even to speculate about the distance between and uniqueness of allosteric and orthosteric ligand binding sites on the A 3 receptor. Nevertheless, there may be some structural interdependency between the two sites, which is indicated also by the fact that the same chemical class of ligands may bind at both. For the A 1 receptor, a single mutation of T277A, had effects on both (i.e., the affinity of agonists greatly diminished and the effect of PD81723 was much less pronounced) (Kourounakis et al., 2001) . The nature and location of the allosteric sites on muscarinic receptors have not been characterized in detail; however, mutation studies showed that residues found important for the binding of gallamine were mainly located at the extracellular face of the receptor. Some of these residues might be part of one of the allosteric sites (Birdsall et al., 2001 ). The fact that many allosteric modulators for muscarinic receptors are polycationic molecules, together with other evidence, suggests that the allosteric site for some modulators may be close to the orthosteric site. The allosteric site of muscarinic receptors is thought to be near the exofacial surface of the receptor (Christopoulos et al., 1998) .
In summary, allosteric modulators for A 3 adenosine receptors were identified and characterized. All of the compounds that showed allosteric enhancement also showed competitive binding properties. However, structure-activity relationships suggested the allosteric effects were separable from competitive antagonism. Hence, it may be possible to find allosteric enhancers that lack antagonistic properties by modifying the structures of these compounds or by screening compounds of other chemical entities.
